Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 117, Issue 18, Pages 9964-9972
Publisher
Proceedings of the National Academy of Sciences
Online
2020-04-21
DOI
10.1073/pnas.1913633117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
- (2020) Yang Liu et al. Cancers
- Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid
- (2020) Yang Liu et al. CLINICAL CANCER RESEARCH
- Triptolide induces oxidative damage in NRK-52E cells through facilitating Nrf2 degradation by ubiquitination via the GSK-3β/Fyn pathway
- (2019) Ji Pan et al. TOXICOLOGY IN VITRO
- Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
- (2019) Pelin Telkoparan-Akillilar et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potential Applications of NRF2 Inhibitors in Cancer Therapy
- (2019) Emiliano Panieri et al. Oxidative Medicine and Cellular Longevity
- CRISPR editing of mutant IDH1 R132H induces a CpG methylation-low state in patient-derived glioma models of G-CIMP
- (2019) Casey J. Moure et al. MOLECULAR CANCER RESEARCH
- Brusatol, an NRF2 inhibitor for future cancer therapeutic
- (2019) Sabrina J. Cai et al. Cell and Bioscience
- Blockade of glutathione metabolism in IDH1-mutated glioma
- (2019) Xiaoying Tang et al. MOLECULAR CANCER THERAPEUTICS
- Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity
- (2018) Jiayu Zhu et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Targeting IDH1-Mutated Malignancies with NRF2 Blockade
- (2018) Yang Liu et al. JNCI-Journal of the National Cancer Institute
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles
- (2017) Farshad Farshidfar et al. Cell Reports
- An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy
- (2016) Jiayu Zhu et al. FREE RADICAL BIOLOGY AND MEDICINE
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
- (2015) R. J. Molenaar et al. CANCER RESEARCH
- Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells
- (2015) XIAOLING DING et al. Molecular Medicine Reports
- Mutational landscape and clonal architecture in grade II and III gliomas
- (2015) Hiromichi Suzuki et al. NATURE GENETICS
- 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
- (2015) Alexandra Borodovsky et al. Oncotarget
- IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
- (2014) A. Kernytsky et al. BLOOD
- Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
- (2014) Jinlong Shi et al. TUMOR BIOLOGY
- The emerging role of the Nrf2-Keap1 signaling pathway in cancer
- (2013) M. C. Jaramillo et al. GENES & DEVELOPMENT
- Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1α and Nrf2
- (2013) Feili Chen et al. PHARMACOGENOMICS
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
- (2012) Peppi Koivunen et al. NATURE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone Demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Protein Nuclear Stabilization
- (2012) Chibawanye I. Ene et al. PLoS One
- -Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas
- (2012) C. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
- (2011) M Fernanda Amary et al. JOURNAL OF PATHOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
- (2011) D. Ren et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
- (2010) T. Jiang et al. CANCER RESEARCH
- Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
- (2010) M. J. Seltzer et al. CANCER RESEARCH
- Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features
- (2010) L. M. Solis et al. CLINICAL CANCER RESEARCH
- Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
- (2010) P. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
- (2009) Yoo Ri Kim et al. JOURNAL OF PATHOLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues
- (2008) Rui Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy
- (2008) A. Singh et al. CANCER RESEARCH
- Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
- (2008) X.-J. Wang et al. CARCINOGENESIS
- Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer
- (2008) Tatsuhiro Shibata et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now